Insulet Flags Manufacturing Issue Affecting 7M Insulin Pods

Dow Jones
05/27

By Katherine Hamilton

 

Insulet is voluntarily correcting certain insulin pod medical devices due to a manufacturing issue that could result in the pods not delivering enough insulin.

The maker of insulin delivery pods for people with diabetes said its Omnipod 5, Omnipod DASH and Omnipod Insulin Management System pods are all part of the correction.

Some pods from specific lots may have a small tear in the tubing just above the skin. If this occurs, insulin could leak outside the pod and result in under-delivery of insulin to the person wearing the pod.

About 7 million pods are included within the scope of the correction, roughly 60% of which have been consumed or are expired. The pods affected by the correction represent about 8.5% of Insulet's production of Omnipods in 2025.

Shares fell 7.5% to $141.50 in after-hours trading Tuesday. Through the close, the stock was down 46% this year.

People using an affected pod may notice wetness on their skin or pod adhesive, or they could detect the smell of insulin, Insulet said. In some cases, the issue may be difficult to detect and go unnoticed.

If patients aren't receiving enough insulin, it could result in high blood glucose levels and potentially lead to diabetic ketoacidosis.

Globally, there have been 24 reports of serious adverse events. No deaths have been reported.

This correction is separate from an earlier voluntary correction Insulet issued in March on certain Omnipod 5 pods in the U.S. It includes certain pod lots distributed in the U.S. and international markets.

Insulet said it identified the cause of the issue and is strengthening its in-process monitoring and quality controls. It is also communicating with affected customers to help them get replacement pods at no cost.

Insulet has enough supply to replace affected pods and doesn't anticipate any disruption to product availability, it said.

Customers should visit Check Pod to confirm whether their pod lot number is included in the correction, Insulet said.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

May 26, 2026 16:41 ET (20:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10